^
Association details:
| Biomarker: | EGFR E709A + EGFR G719C |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
Excerpt:
The E709A+G719C double mutation was found in an 80-year-old female never smoker with advanced adenocarcinoma of the lung with acinar and BAC characteristics….Erlotinib was subsequently given at the starting dose of 150 mg daily, reduced to 100 and 75 mg due to G3 skin toxicity. The tumor assessment, performed 2 months after the beginning of the treatment, showed a partial response (PR), still maintained after 10 months.
DOI:
10.1097/JTO.0b013e318227e8c6
